Shanghai Xihua Scientific Co.,Ltd.(Xihua) was established in 2015. The headquarters is located in the core area of the Pharmaceutical Valley in Zhangjiang Hi-Tech Park, Shanghai. We have subsidiaries Xihua PharmaTech, Xihua Clinical , Suzhou Xihua, Xihua Pharmaceuticals, Chuzhou Xihua, etc. Besides, Xihua holds Primera Analytical Solutions Corp.(U.S.) and TCM Groups (U.S.) as well. With drug testing as the core, Xihua provides global pharmaceutical companies with high quality and efficient full process and integrated services from self-medicated development to market approval.
Providing integrated drug development services
Reducing time costs;
Speeding up the R&D process;
Improving the success rate of drug development and shortening time to market for clients.
International service capability
All core team members have rich experience;
With perfect quality assurance system;
Able to meet customers' needs for China-US dual declaration and global multi-center clinical declaration
Leading technology advantage
Data as of June 30, 2022, it has passed more than 110 on-site inspections by national or local drug regulatory authorities and the FDA;
Equipped with a leading and abundant technology platform;
Actively laying out cutting-edge technologies with first-mover advantage in the field of gene therapy.
Technical talents and resources with unique advantages in various drug R&D service fields, and the management team and PIs are from domestic/international well-known CROs or pharmaceutical companies, who are well versed in domestic and international drug R&D laws and regulations and quality systems to provide customers with high-quality research results.
First-mover advantage in bioanalysis
Xihua has been deeply engaged in bioanalysis since its establishment in 2015, and has accumulated rich experience in the field of bioanalysis, which makes it an industry leader in terms of business scale, quality and reputation in this segment.
Wide range of customers and high stickiness
We have accumulated rich industry experience and established a good reputation, and successfully expanded the service of providing a full range of new drug development services to large domestic and foreign pharmaceutical companies and many emerging well-known innovative biotechnology companies. Data as of June 30, 2022, the company has served nearly 600 domestic and international customers, including both most of top 50 domestic pharmaceutical companies and the top 10 global pharmaceutical companies, as well as small and medium-sized Biotech companies.